Skip to main content
Premium Trial:

Request an Annual Quote

M2Gen Expands Partnership With Discovery Life Sciences

NEW YORK – M2Gen said Friday that it has expanded its partnership with Discovery Life Sciences to provide pipeline analysis for tumor-normal and tumor-only somatic mutation identification for whole-exome sequences, as well as gene expression and fusion detection from tumor RNA sequencing.

Tampa, Florida-based M2Gen's has had a partnership with Discovery Life Sciences, a resident associate company of the HudsonAlpha Institute for Biotechnology, since 2016. Over the last four years, the two entities have built a standardized workflow of preclinical and sequencing technologies to analyze both liquid and solid biospecimens.

Discovery Life Sciences purchased the HudsonAlpha Genomic Services Lab in March 2019 and renamed it HudsonAlpha Discovery.

Notably, M2Gen and Discovery Life Sciences have helped build the Oncology Research Information Exchange Network's (ORIEN) Avatar research database. Informatics firm M2Gen has been involved with ORIEN Avatar since the database's launch in June 2016.

"We are excited to expand our longstanding successful collaboration with Discovery Life Sciences by providing our oncology-focused bioinformatics services and solutions to Discovery," Oliver Hampton, VP of bioinformatics and biostatistics at M2Gen, said in a statement.

"This agreement demonstrates the power of our multi-disciplinary expertise to access, curate, harmonize and interpret complex clinical and molecular data sets and to leverage our high-depth database for the benefit of interpreting and adding value to information generated by third parties," added M2Gen President and CEO Helge Bastian.